Press Releases | May 16, 2019 |

Visiopharm Welcomes Adrian Arechiga Arechiga as Chief Marketing Officer

Visiopharm is delighted to announce Adrian Arechiga Ph.D. as its new Chief Marketing Officer. Highly experienced as a Senior Marketing Director, Adrian has an impressive track record of working internationally in the biopharma, oncology diagnostics, and life science industries.

Adrian will be instrumental in leading Visiopharm’s marketing through its expansion following significant investment. He will be based in Visiopharm’s new office in Germany. 

“We are delighted to welcome such a talented and experienced Chief Marketing Officer to the company at this phase in our growth,” said Michael Grunkin Ph.D., CEO, and co-founder of Visiopharm. “Tissue image analysis is becoming increasingly important in drug-diagnostic co-development, and cancer diagnostics. With his strong scientific background, and practical experience in this field, Adrian is ideally positioned to communicate the benefits of this emerging and rapidly evolving technology, in a clear, concise and scientifically credible way, that has practical utility to scientists and pathologists.”

Adrian joins Visiopharm from Definiens, where he was the Senior Director of Global Brand and Product Marketing. He has over ten years’ experience working in the biotechnology, oncology diagnostics, and pharmaceutical industries, and holds a doctorate in Molecular Immunology and an MBA in Sustainable Management.

His role will initially be focused on strengthening the brand narrative and communicating digital pathology’s potential applications across tissue-diagnostics through a new content platform.
“I am excited to join Visiopharm, with a strong pipeline of new products and technologies, it Is a great time to join the team and communicate the value that Visiopharm delivers,” he said. “I look forward to developing our marketing capabilities and brand as we expand presence and market share globally.”

Following a €13.3 million investment in 2018 to fuel its international growth, Visiopharm is growing rapidly in both revenue and size. With a headcount approaching 100 employees, Visiopharm is the largest quantitative digital pathology company in the world.

Do you want to know more – contact us

Share this article

Share the link on Twitter Share the link on LinkedIn

About Visiopharm A/S

Visiopharm® is a world leader in Augmented Pathology™ solutions. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and diagnostic pathology labs all over the world use Visiopharm’s technology for tissue-based research and diagnostics.
Its solutions use the newest advancements in artificial intelligence and deep learning to make the most comprehensive, highly configurable and accurate services for tissue analysis available on the market today.
Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses in more than 38 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in London and Broomfield, Colorado.
For Visiopharm logos and pictures: Press Photos

Learn everything about digital pathology
Knowledge Library

Latest news

Your message has been successfully sent!